Argus II/ORCAM Device Study
Primary Purpose
Retinitis Pigmentosa
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Argus II Eyeglasses
ORCAM
Sponsored by
About this trial
This is an interventional device feasibility trial for Retinitis Pigmentosa
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of advanced retinitis pigmentosa
- Subjects must have an Argus II device implanted to be eligible for this study
- Subjects must be familiar with using their Argus II device
Exclusion Criteria:
- No Argus II implant
Sites / Locations
- Mayo Clinic in Rochester
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Adults with Retinitis Pigmentosa using ARGUS II
Arm Description
Subjects will use the ORCAM system mounted onto the Argus II eyeglasses.
Outcomes
Primary Outcome Measures
Number of Subjects Who Are Able to Use the ORCAM device With the Argus II Device at the End of the Study
Subjects will be familiar with using their retinal prosthesis, the Argus II Device. At baseline, the ORCAM device will be mounted on the Argus II eyeglasses.
Secondary Outcome Measures
Full Information
NCT ID
NCT03248388
First Posted
August 8, 2017
Last Updated
January 11, 2022
Sponsor
Mayo Clinic
Collaborators
Second Sight Medical Products
1. Study Identification
Unique Protocol Identification Number
NCT03248388
Brief Title
Argus II/ORCAM Device Study
Official Title
Utility of Visual Pattern Recognition Technology in Retinal Prosthesis Patients: the ARGUSII/ORCAM Device Study
Study Type
Interventional
2. Study Status
Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
August 31, 2017 (Actual)
Primary Completion Date
October 15, 2020 (Actual)
Study Completion Date
October 15, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
Collaborators
Second Sight Medical Products
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is being done to determine if wearable text-to-speech (TTS) and visual pattern recognition (VPR) technology can be used to extend the capabilities of the Argus II to allow patients to read and recognize faces and objects.
The Argus II retinal prosthesis can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition. The FDA has approved the Argus II as a humanitarian device.
Present-day wearable text-to-speech converters are also capable of object and face recognition. Such systems have been developed to assist with these tasks in patients with severe low-vision. ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.
Detailed Description
The Orcam device will be mounted onto the Argus II eyeglasses. The subject will be asked to use the Orcam device with and without the Argus II. After a half-day interactive training session with the Orcam device, the investigators will interview the subject with a questionnaire. The investigators will then contact the subject every two weeks via a telephone call for two months (4 phone interviews). The investigators will then ask the subject to return to Mayo Clinic to demonstrate their ability to use the Argus II and Orcam together and separately. These sessions will be videotaped.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Retinitis Pigmentosa
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Adults with Retinitis Pigmentosa using ARGUS II
Arm Type
Experimental
Arm Description
Subjects will use the ORCAM system mounted onto the Argus II eyeglasses.
Intervention Type
Device
Intervention Name(s)
Argus II Eyeglasses
Intervention Description
The Argus II Eyeglasses (retinal prosthesis) can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition.
Intervention Type
Device
Intervention Name(s)
ORCAM
Intervention Description
ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.
Primary Outcome Measure Information:
Title
Number of Subjects Who Are Able to Use the ORCAM device With the Argus II Device at the End of the Study
Description
Subjects will be familiar with using their retinal prosthesis, the Argus II Device. At baseline, the ORCAM device will be mounted on the Argus II eyeglasses.
Time Frame
End of study, approximately 4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of advanced retinitis pigmentosa
Subjects must have an Argus II device implanted to be eligible for this study
Subjects must be familiar with using their Argus II device
Exclusion Criteria:
- No Argus II implant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Raymond Iezzi
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
12. IPD Sharing Statement
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials
Learn more about this trial
Argus II/ORCAM Device Study
We'll reach out to this number within 24 hrs